Physicians and the pharmaceutical industry: A dysfunctional relationship

Perspectives in Biology and Medicine

Volumn 46, Issue 2, 2003, Pages 254-272

  Fisher, Morris A ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL TARTRATE; LORATADINE; NEW DRUG; PENTAZOCINE;

DRUG ABUSE; DRUG COST; DRUG FATALITY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL DISEASE; MIGRAINE; PAIN; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; REVIEW; UNITED STATES;

EID: 0038217008     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2003.0019     Document Type: Review

References (80)

1. Abraham, J. 1995. Science, politics, and the pharmaceutical industry: Controversy and bias in drug regulation. New York: St. Martin's Press.
2. Anderson, C. 1999. Drug firms said to pay less in taxes. Boston Globe (16 Dec.).
3. Angell, M. 2000a. Is academic medicine for sale? N. Engl. J. Med. 342:1516-18.
4. Angell, M. 2000b. The pharmaceutical industry: To whom is it accountable? N. Engl. J. Med. 342:1902-4.
5. Austin, R. P. 1983. Diversion of butorphanol. Am. J. Hosp. Pharmacy 40:1306.
6. Avorn, J., M. Chen, and R. Hartley. 1982. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am. J. Med. 73:4-8.
7. Barnes, R. H., Director, Federal State Relations, FDA. 1995. Memorandum, 28 Nov.
8. Bodenheimer, T. 2000. Uneasy alliance: Clinical investigators and the pharmaceutical industry. N. Engl. J. Med. 342:1539-44.
9. Brewer, T., and G. A. Colditz. 1999. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. JAMA 281:824-29.
10. Butorphanol nasal spray for pain. 1993. Med. Lett. Drugs Ther. 35:105-6.
11. Caplan, L. R., C. Thomas, and G. Banks. 1982. Central nervous system complications of addiction to "T's and Blues." Neurology 32:623-28.
12. Cho, M. K., et al. 2000. Policies on faculty conflicts of interest at US universities. JAMA 284:2203-8.
13. Chren, M. M., and C. S. Landefeld. 1994. Physicians' behavior and their interactions with drug companies: A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 271:684-89.
14. Congressional Research Service. 1999. Memorandum. Federal taxation of the drug industry from 1990 to 1996.
15. DiMasi, J. A., et al. 1991. Cost of innovation in the pharmaceutical industry. J. Health Econ. 10:107-42.
16. Drake, D., and M. Uhlman. 1993. Making medicine, making money. Kansas City, MO: Andrews and McMeel.
17. Drug Abuse Advisory Committee (DAAC), FDA, 1 June 1978.
18. Drug Abuse Advisory Committee (DAAC), FDA, 4 Feb. 1991.
19. European Federation of Pharmaceutical Industries and Associations (EFPIA). 2000. The pharmaceutical industry in figures.
20. Fisher, M. A., and S. Glass. 1997. Butorphanol (Stadol): A study in problems of current drug information and control. Neurology 48:1156-60.
21. Flanagin, A., et al. 1998. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280:222-24.
22. The 2001 Fortune 500. 2001. Fortune (16 April) 〈http://www.fortune.com〉.
23. Freudenheim, M., and M. Petersen. 2001. The drug-price express runs into a wall. NY Times (23 Dec.).
24. Gerth, J., and S. G. Stolberg. 2000. Drug makers reap profits on tax-backed research. NY Times (23 April).
25. Getz, K. A. 1999. AMC's rekindling clinical research partnerships with industry. Boston: Centerwatch.
26. Gibbons, R. V., et al. 1998. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J. Gen. Intern. Med. 13:213-15.
27. Glassman, P. A., J. Hunter-Hayes, and T. Nakamura. 1999. Pharmaceutical advertising revenue and physician organizations: How much is too much? West. J. Med. 171:234-38.
28. Guldal, D., and S. Semin. 2000. The influence of drug companies' advertising programs on physicians. Int. J. Health Serv. 30:585-95.
29. Gunther, J. K., Ph.D., Director, Worldwide Regulatory Affairs, Bristol-Meyers Squibb, 1995. Letter to Robert Bradford, M.D., Acting Director, Pilot Drug Evaluation Staff, Center of Drug Evaluation and Research, FDA, 24 Feb.
30. Gunther, J. K., Ph.D., Director, Worldwide Regulatory Affairs, Bristol-Meyers Squibb, 1996. Letter to Robert Bradford, M.D., Acting Director, Pilot Drug Evaluation Staff, Center of Drug Evaluation and Research, FDA, 24 May.
31. Hall, S. S. 2001. Prescription for profit. NY Times Mag. (11 March).
32. Harris, G. 2000. Drug firms, stymied in the lab, become marketing machines. Wall Street J. (6 July).
33. Hoffert, M. J., et al. 1995. Transnasal butorphanol in the treatment of acute migraine. Headache 35:65-69.
34. Hopper, J. A., M.W. Speece, and J. L. Musial. 1997. Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. J. Gen. Intern. Aged. 12:639-42.
35. Kessler, D. A., et al. 1994. Therapeutic-class wars: Drug promotion in a competitive marketplace. N. Engl. J. Med. 331:1350-53.
36. Kolata, G. 2000. Sharing of profits is debated as the value of tissue rises. NY Times (15 May).
37. Korn, D. 2000. Conflicts of interest in biomedical research. JAMA 284:2234-38.
38. Langreth, R. 1998. Drug marketing drives many clinical trials. Wall Street J. (16 Nov.).
39. Lazarou, J., B. H. Pomeranz, and P. N. Corey. 1998. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279:1200-1205.
40. Lo, B., L. E. Wold, and A. Berkeley. 2000. Conflict-of-interest policies for investigators in clinical trials. N. Engl. J. Med. 343:1616-20.
41. Lurie, N., et al. 1990. Pharmaceutical representatives in academic medical centers: Interactions with faculty and housestaff. J. Gen. Intern. Med. 5:240-43.
42. Martin, J. B., and D. L. Kasper. 2000. In whose best interest? Breaching the academic-industrial wall. N. Engl. J. Med. 343:1646-49.
43. May, C. D. 1961. Selling drugs by "educating" physicians. J. Med. Educ. 36:1-23.
44. McCormick, B. B., et al. 2001. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 286:1994-99.
45. McKinney, W. P., et al. 1990. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 264:1693-97.
46. Moore, T. J. 1995. Deadly medicine. New York: Simon & Schuster.
47. National Institute for Health Care Management. 2001. Prescription drugs and mass media advertising. Available at 〈www.nihcm.org〉.
48. National Institute for Health Care Management. 2002. Changing patterns of pharmaceutical innovation. Available at 〈www.nihcm.org〉.
49. National Institutes of Health (NIH). 2000. NIH contributions to pharmaceutical development. Administrative document, Feb.
50. New Drug Application 17-857. FDA, 1978.
51. New Drug Application 19-890. FDA, 1991.
52. New Mexico Board of Pharmacy. 1994. Transcript of proceedings, 22 Aug.
53. Office of Technology Assessement, U.S. Congress. 1993. Pharmaceutical R&D: Costs, risks and rewards.
54. Pear, R. 2002. Senate kills plan for drug benefits through Medicare. NY Times (1 Aug.).
55. Petersen, M. 2001. Increased spending on drugs is linked to more advertising. NY Times (21 Nov.).
56. Petersen, M. 2002a. Merck is said to limit perks in marketing to physicians. NY Times (18 Jan.).
57. Petersen, M. 2002b. Vermont to require drug makers to disclose payment to doctors. NY Times (13 June).
58. Pharmaceutical Research and Manufacturers of America. 2001. Available at 〈www.phrma.org/publications/pulblications/profile00/chap3.phtml〉.
59. Public Citizen Health Research Group. 2000a. Health Letter 16:8, 10.
60. Public Citizen Health Research Group. 2000b. Worst Pills, Best Pills News 6:41-42.
61. Public Citizen Health Research Group. 2001. Rx R&D myths: The case against the drug industry's "scare card." Available at 〈www.citizen.org/hrg/〉.
62. Rapoport, A. M. 1994. Severe headache: Focus on migraine. Neurology 44 (suppl. 3):6-28.
63. Robbins, L. 1993. Stadol nasal spray: Treatment for migraine? Headache 33:320.
64. Robeznieks, A. 2002. Pharmacy group details what drug reps can give physicians. AM News 45:1-2.
65. Saper, J. R. 1995. Transnasal butorphanol for acute migraine. Topics Pain Management 10:45-47.
66. Shnitzler, D., Regulatory Review Office, Division of Drug Marketing, Advertising and Communications, FDA. 1996. Letter to Kathryn Bishburg, Pharm. D., Associate Director, Promotional Compliance, Bristol-Meyers Squibb, 11 April; reply dated 27 June 1996.
67. Smith, S. G., and W. M. Davis. 1984. Non-medical use of butorphanol and diphendy-dramine. JAMA 252:1010.
68. Stelfox, H. T., et al. 1998. Conflict of interest in the debate over calcium-channel antagonists. N. Engl. J. Med. 338:101-6.
69. Stolberg, S. G. 1998. Gifts to science researchers have strings, study finds. NY Times (1 April).
70. Stolberg, S. G., and J. Gerth. 2000. How companies stall generics and keep themselves healthy. NY Times (23 July).
71. Vandam, L. R. 1980. Butorphanol. N. Engl. J. Med. 302:381-84.
72. Wayne, L., and M. Petersen. 2001. A muscular lobby rolls up its sleeves. NY Times (4 Nov.): sec. 3:1, 13.
73. Wazana, A. 2000. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283:373-80.
74. Wiggins, S. N. 1987. The cost of developing a new drug. Pharmaceutical Manufacturers Association, June.
75. Wilkes, M. S., B. H. Doblin, and M. F. Shapiro. 1992. Pharmaceutical advertisements in leading medical journals: Experts' assessments. Ann. Intern. Med. 116:912-19.
76. Wilms, H. G., Director, Federal State Relations, FDA. 1994. Memorandum, 24 June.
77. Wolfe, S. M. 1996. Why do American drug companies spend more than $12 billion a year pushing drugs? J. Gen. Intern. Med. 11:637-39.
78. Wood, A. J. J. 2000. Thrombotic thrombocytopenic purpura and clopidogrel: A need for new approaches to drug safety. N. Engl. J. Med. 342:1824-26.
79. Wood, A. J. J., C. M. Stein, and R. Woosley. 1998. Making medicines safer: The need for an independent drug safety board. N. Engl. J. Med. 339:1851-54.
80. Ziegler, M. G., P. Lew, and B. C. Singer. 1995. The accuracy of drug information from pharmaceutical sales representatives. JAMA 273:1296-98.